Niki BioSolutions names Thomas Freeburg chief financial officer, effective September 1, 2026
Niki BioSolutions appointed Thomas Freeburg as its Chief Financial Officer under an employment agreement, with the appointment effective September 1, 2026, for a two-year term that either party can end on 45 days' notice. The filing says his base salary is $250,000, with $25,000 of each monthly payment deferred until the company receives certain funding, and he is eligible for an annual bonus of up to 50% of base salary plus 50,000 stock options at $8.83 per share.
Key points
- Board appointed Thomas Freeburg as CFO on October 9, 2026, effective as of September 1, 2026
- Base salary of $250,000, rising to $275,000 upon receipt of additional company funding
- Eligible for an annual bonus of up to 50% of base salary and 50,000 stock options priced at $8.83 per share
- Freeburg previously served as CFO of Interpace Biosciences, Inc. from February 2021 through March 2023
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.